[go: up one dir, main page]

MX2020007032A - Composicion que comprende probioticos y polipeptido que tiene afinidad de union para ige y uso de la misma. - Google Patents

Composicion que comprende probioticos y polipeptido que tiene afinidad de union para ige y uso de la misma.

Info

Publication number
MX2020007032A
MX2020007032A MX2020007032A MX2020007032A MX2020007032A MX 2020007032 A MX2020007032 A MX 2020007032A MX 2020007032 A MX2020007032 A MX 2020007032A MX 2020007032 A MX2020007032 A MX 2020007032A MX 2020007032 A MX2020007032 A MX 2020007032A
Authority
MX
Mexico
Prior art keywords
ige
composition
probiotics
polypeptide
binding affinity
Prior art date
Application number
MX2020007032A
Other languages
English (en)
Inventor
Myoung Ho Jang
Young Chul Sung
Zungyoon Yang
Original Assignee
Gi Innovation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gi Innovation Inc filed Critical Gi Innovation Inc
Publication of MX2020007032A publication Critical patent/MX2020007032A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición que contiene, como ingredientes activos, probióticos y un polipéptido con capacidad de unión a IgE. En particular, se identificó un efecto sinérgico de disminución notable de la alergia alimentaria en el momento de la administración combinada de probióticos y una proteína recombinante que contiene un dominio extracelular de una subunidad alfa de un receptor Fc de IgE de conformidad con la presente invención. Por lo tanto, se espera que la composición de la presente invención sea altamente aplicable industrialmente debido a que puede presentar un efecto terapéutico notable sobre una enfermedad alérgica mediada por IgE en comparación con las composiciones farmacéuticas convencionales.
MX2020007032A 2018-01-12 2019-01-14 Composicion que comprende probioticos y polipeptido que tiene afinidad de union para ige y uso de la misma. MX2020007032A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180004421 2018-01-12
PCT/KR2019/000524 WO2019139434A1 (ko) 2018-01-12 2019-01-14 프로바이오틱스 및 ige에 결합능이 있는 폴리펩티드를 포함하는 조성물 및 이의 용도

Publications (1)

Publication Number Publication Date
MX2020007032A true MX2020007032A (es) 2020-12-03

Family

ID=67218660

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007032A MX2020007032A (es) 2018-01-12 2019-01-14 Composicion que comprende probioticos y polipeptido que tiene afinidad de union para ige y uso de la misma.

Country Status (18)

Country Link
US (1) US12128076B2 (es)
EP (1) EP3738599B1 (es)
JP (1) JP7041272B2 (es)
KR (1) KR102038679B1 (es)
CN (1) CN111587118B (es)
AU (1) AU2019206205B2 (es)
BR (1) BR112020013818A2 (es)
CA (1) CA3086224A1 (es)
CL (1) CL2020001800A1 (es)
ES (1) ES2969110T3 (es)
IL (1) IL275593B (es)
MX (1) MX2020007032A (es)
MY (1) MY205046A (es)
PE (1) PE20210108A1 (es)
PH (1) PH12020551069A1 (es)
SG (1) SG11202005863TA (es)
TW (1) TWI737955B (es)
WO (1) WO2019139434A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019135668A1 (ko) * 2018-01-08 2019-07-11 주식회사 프로젠 Ige fc 수용체의 알파 서브유닛의 세포외 도메인, 이를 포함하는 약학적 조성물 및 이의 제조방법
EP3927375A4 (en) * 2019-02-20 2022-11-23 Siolta Therapeutics, Inc. COMPOSITIONS FOR THE TREATMENT OF DISEASES
CN114080398B (zh) * 2019-07-08 2024-05-31 Gi医诺微新 包含IgE Fc受体的α亚基的胞外结构域且具有高唾液酸含量的多肽二聚体及包含其的药物组合物
CN116348605A (zh) * 2020-07-17 2023-06-27 Gi 医诺微新 包含IgE Fc受体α亚基胞外结构域和抗IL-4R抗体的融合蛋白及其应用
KR20220011931A (ko) * 2020-07-22 2022-02-03 (주)지아이이노베이션 IgE Fc 수용체를 포함하는 융합단백질 및 이를 포함하는 개 알레르기성 질환 치료 용도

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH092959A (ja) 1995-06-16 1997-01-07 Yakult Honsha Co Ltd ＩｇＥ抗体産生抑制剤および抗アレルギー剤
JPH10309178A (ja) 1997-05-09 1998-11-24 Wakamoto Pharmaceut Co Ltd ビフィズス菌を有効成分とする抗アレルギー剤および醗酵食品
JP2000095697A (ja) * 1998-09-18 2000-04-04 Advance Co Ltd 抗アレルギー剤
AUPQ415899A0 (en) * 1999-11-19 1999-12-16 Vasse Research Institute Pty Ltd Compositions for and methods of treatment of allergic diseases
EP1239032A1 (en) 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Lactic acid bacteria as agents for treating and preventing allergy
JP4212838B2 (ja) 2002-06-26 2009-01-21 カルピス株式会社 抗アレルギー剤
JP2009067679A (ja) 2005-12-27 2009-04-02 Univ Of Tokushima 抗ヒスタミン作用を有する医薬
WO2008028068A2 (en) * 2006-08-30 2008-03-06 Genentech, Inc. NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES
US20100303777A1 (en) 2006-12-14 2010-12-02 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
JP5577243B2 (ja) 2007-05-30 2014-08-20 ポステク アカデミー−インダストリー ファウンデイション 免疫グロブリン融合タンパク質
EP2065048A1 (en) 2007-11-30 2009-06-03 Institut Pasteur Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation
CA2713525A1 (en) 2008-02-06 2009-08-13 The Procter & Gamble Company Compositions methods and kits for enhancing immune response to a respiratory condition
WO2010013143A2 (en) * 2008-08-01 2010-02-04 Institut Pasteur Methods for inhibiting mast cell activation and treating mast cell-dependent inflammatory diseases and disorders using lactobacillus
EP2853545B8 (en) 2008-09-17 2023-04-05 Xencor, Inc. Antibody specific for IgE
SI2494356T1 (sl) 2009-10-26 2017-07-31 Genentech, Inc. Preizkusi za detektiranje protiteles, specifičnih za terapevtska protitelesa proti IgE, in njihova uporaba pri anafilaksi
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
KR20120135865A (ko) 2011-06-07 2012-12-17 (주)네오팜 ＦｃεＲＩ의 수용성 단편을 포함하는 복합체 및 이를 포함하는 ＩｇＥ 매개 알레르기성 질환 치료용 조성물
WO2012169735A2 (ko) * 2011-06-07 2012-12-13 (주)네오팜 FCεRI의 수용성 단편을 포함하는 복합체 및 이를 포함하는 IGE 매개 알레르기성 질환 치료용 조성물
CN103169733B (zh) * 2011-12-26 2014-11-12 浙江贝因美科工贸股份有限公司 复合益生菌、其在治疗过敏性疾病中的应用及孕产妇防过敏益生菌冲剂
AR091305A1 (es) 2012-01-31 2015-01-28 Genentech Inc ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO
TWI691512B (zh) 2015-02-20 2020-04-21 日商橘生藥品工業股份有限公司 Ｆｃ融合高親和性ＩｇＥ受體α鏈
JP2018515426A (ja) * 2015-03-12 2018-06-14 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア 細菌組成物およびその使用方法
KR101778734B1 (ko) 2016-03-11 2017-09-18 대한민국(농촌진흥청장) 비피도박테리움 롱검 kacc 91563으로부터 분리된 esbp 및 이를 이용한 항알레르기 조성물
WO2019135668A1 (ko) * 2018-01-08 2019-07-11 주식회사 프로젠 Ige fc 수용체의 알파 서브유닛의 세포외 도메인, 이를 포함하는 약학적 조성물 및 이의 제조방법
WO2019135666A1 (ko) * 2018-01-08 2019-07-11 주식회사 프로젠 Ige fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 약학적 조성물

Also Published As

Publication number Publication date
CL2020001800A1 (es) 2020-10-30
RU2020122021A (ru) 2022-02-14
CA3086224A1 (en) 2019-07-18
KR102038679B1 (ko) 2019-10-30
IL275593A (en) 2020-08-31
CN111587118B (zh) 2023-11-21
SG11202005863TA (en) 2020-07-29
AU2019206205A1 (en) 2020-06-25
US12128076B2 (en) 2024-10-29
JP2021510689A (ja) 2021-04-30
EP3738599C0 (en) 2023-12-27
IL275593B (en) 2022-01-01
KR20190086396A (ko) 2019-07-22
BR112020013818A2 (pt) 2020-12-01
MY205046A (en) 2024-09-29
JP7041272B2 (ja) 2022-03-23
AU2019206205B2 (en) 2025-04-10
EP3738599B1 (en) 2023-12-27
PE20210108A1 (es) 2021-01-19
TWI737955B (zh) 2021-09-01
EP3738599A1 (en) 2020-11-18
US20220347236A1 (en) 2022-11-03
WO2019139434A1 (ko) 2019-07-18
ES2969110T3 (es) 2024-05-16
PH12020551069A1 (en) 2021-09-06
TW201932129A (zh) 2019-08-16
CN111587118A (zh) 2020-08-25
EP3738599A4 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
PH12020551069A1 (en) Composition comprising probiotics and polypeptide having binding affinity for ige and use thereof
MX2019007144A (es) Nuevos agonistas de tnfr y sus usos.
MY198425A (en) Glp-1 Compositions and uses Thereof
WO2019191633A3 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
MX2022013945A (es) Nuevas proteinas de union a repeticiones de anquirina y sus usos.
MX2018005193A (es) Proteinas de doble funcion y composicion farmaceutica que comprende las mismas.
EA202091342A2 (ru) Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения
MY162324A (en) Immunomodulatory polypeptides derived from il-2 and their use thereof in the therapeutic of cancer and chronic infections
GT201500049A (es) Proteinas de fusiòn para el tratamiento de un sìndrome metàbolico
TN2012000372A1 (en) Fibronectin based scaffold domain proteins that bind il-23
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
MY209615A (en) Extracellular domain of alpha subunit of ige fc receptor, pharmaceutical composition comprising same and method for producing same
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
MX386014B (es) Citocina fusionada a fc heterodimérico, y composición farmacéutica que comprende la misma.
PH12020551500A1 (en) Viscosity reduction of highly concentrated protein formulations
MX2021008207A (es) Proteínas de fusión multifuncionales y usos de las mismas.
JP2015532307A5 (es)
MY194925A (en) Composition of fish skin collagen peptides and use thereof as a drug
MX347229B (es) Antagonistas de péptido de la familia cgrp de calcitonina de hormonas de péptido y su uso.
IL277790A (en) Human neuregulin-1 recombinant chimeric protein preparations and methods of using them
MX2023009921A (es) Formulaciones de proteinas de fusion ace2-fc.
MX2023004933A (es) Proteinas de fusion de ace2 y usos de las mismas.
MX2019012506A (es) Formulaciones estables de proteinas de dominio andamio a base de fibronectina que se unen a miostatina.
IL289679A (en) A dimer polypeptide with a high sialic acid content, containing an extracellular domain of the alpha subunit of the ige fc receptor and a pharmaceutical preparation containing it